Form 4: CareDx General Counsel Reports Stock Transactions

CareDx's Secretary and General Counsel, Jeffrey Adam Novack, reported the acquisition of restricted stock units and performance-based units, alongside tax-related dispositions and a sale under a 10b5-1 trading plan.

Summary

• Jeffrey Adam Novack, Secretary and General Counsel of CareDx, Inc., reported multiple transactions involving the company's common stock.
• On February 2, 2026, Novack acquired 33,000 shares through Restricted Stock Units (RSUs) and 4,342 shares through Performance Restricted Stock Units (PRSUs).
• The PRSUs were earned after the achievement of specific performance criteria, certified by the Compensation and Human Capital Committee on February 2, 2026.
• Also on February 2, 2026, 2,492 shares were withheld by CareDx at a price of $20.42 to cover tax obligations related to the PRSU vesting, and 2,970 shares were withheld at $20.42 for RSU vesting tax obligations.
• On February 3, 2026, Novack sold 4,441 shares of common stock at an average price of $20.5553.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025.
• Following these transactions, Novack's direct beneficial ownership stands at 125,364 shares of CareDx common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing. While there was a sale of shares, it was pre-planned under a 10b5-1 plan, and the executive also received significant new equity grants (RSUs and PRSUs), indicating continued alignment with company performance and future growth.

Positives

• Acquisition of 33,000 shares via Restricted Stock Units (RSUs) on February 2, 2026, indicating continued equity compensation.
• Earning of 4,342 shares via Performance Restricted Stock Units (PRSUs) on February 2, 2026, signifying the achievement of specific performance criteria.

Negatives

• Disposition of 2,492 shares at $20.42 to satisfy tax withholding obligations related to PRSU vesting.
• Disposition of 2,970 shares at $20.42 to satisfy tax withholding obligations related to RSU vesting.
• Sale of 4,441 shares at an average price of $20.5553 on February 3, 2026, reducing direct beneficial ownership.

Future Outlook

The RSU grant includes a vesting schedule where one-third will vest on April 6, 2027, and the remaining two-thirds will vest in equal quarterly installments over the subsequent eight quarters, with full vesting by the third anniversary of April 6, 2027, contingent on continuous employment.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common practice for executives to manage their equity holdings in a pre-planned, compliant manner. These transactions provide transparency into executive compensation and personal financial planning, rather than direct operational insights into CareDx's market position or competitive landscape.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, could be perceived as a slight negative, though the concurrent receipt of new equity grants balances this. The transparency of the 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: The vesting of RSUs and PRSUs for the General Counsel reflects standard executive compensation practices, which can be a positive for employee morale regarding equity incentives.

Next Steps

• One-third of the 33,000 RSUs will vest on April 6, 2027.
• The remaining two-thirds of the RSUs will vest in equal quarterly installments over the subsequent eight quarters.
• 100% of the RSUs will be vested on the third anniversary of April 6, 2027, subject to continuous employment.

Key Dates

Recommendation

The filing details routine insider transactions, including the acquisition of new equity awards and a pre-planned sale under a 10b5-1 plan. While the sale reduces the executive's direct holdings, the significant RSU and PRSU grants demonstrate continued long-term alignment. These transactions are generally expected and do not signal a fundamental shift in the company's prospects, thus a 'hold' recommendation is appropriate for existing investors, with new investors advised to consider broader company fundamentals.

Keywords

CareDx, CDNA, Jeffrey Adam Novack, Form 4, Insider Trading, Restricted Stock Units, Performance Restricted Stock Units, RSU, PRSU, Stock Sale, 10b5-1 Plan, Beneficial Ownership, Equity Compensation